Toggle light / dark theme

Over 300 Women Share Experiences, Treatments for Painful, Common Chronic Conditions

CureTogether, a Health 2.0 Startup based in Silicon Valley, has released the first crowdsourced books on vulvodynia and endometriosis: two common, poorly understood conditions causing daily pain for millions of women. Assembled from the input of 190 and 137 women living with these respective conditions, “Vulvodynia Heroes” and “Endometriosis Heroes” are the product of an ongoing online research study at http://www.curetogether.com.

“Patients came together and decided what symptoms and treatments they wanted to track. They went on to diligently gather detailed, quantitative data on their bodies and experiences,” said Alexandra Carmichael, co-Founder of CureTogether. “The hope of this book is to spread awareness, reach out to people in pain who may not have heard of endometriosis, and increase interest and funding for future research.”

“These heroes are pioneers not just in investigating their own condition, but in developing self-cure practices that others can follow.”, said Gary Wolf, Contributing Editor of Wired and Blogger at The Quantified Self. “Many other women who are suffering will find this very helpful and inspiring,” said Elizabeth Rummer, MSPT at the Pelvic Health and Rehabilitation Center in San Francisco. A patient with endometriosis added, “This is great. I am just starting to really appreciate what awesome power CureTogether can have.”

Endometriosis is a painful chronic condition that affects 5–10% of women, and vulvodyna affects up to 16% of women at some point in their lives. They are two of the most active condition communities at CureTogether, with information about symptoms, treatments, and causes added by over 300 women. The books are available at http://www.curetogether.com/VHeroes and http://www.curetogether.com/EHeroes.

About CureTogether

CureTogether launched in 2008 to help people anonymously track and compare health data — to better understand their bodies, make more informed treatment decisions and contribute data to research. Starting with 3 conditions (Migraine, Endometriosis and Vulvodynia), its members have since expanded it to support 228 conditions.

*Please note that the information in Vulvodynia Heroes and Endometriosis Heroes and at CureTogether.com does not constitute medical advice.

For more information, please contact Alexandra Carmichael at 650−533−2163 or [email protected]

If a pandemic strikes and hundreds of millions are at risk, we won’t have enough vaccines for everybody, at least not within the time window where vaccines would help. But a new strategy could help use the vaccines we have more effectively:

Researchers are now proposing a new strategy for targeting shots that could, at least in theory, stop a pandemic from spreading along the network of social interactions. Vaccinating selected people is essentially equivalent to cutting out nodes of the social network. As far as the pandemic is concerned, it’s as if those people no longer exist. The team’s idea is to single out people so that immunizing them breaks up the network into smaller parts of roughly equal sizes. Computer simulations show that this strategy could block a pandemic using 5 to 50 percent fewer doses than existing strategies, the researchers write in an upcoming Physical Review Letters.

vaccine-targeting.jpg

So you break up the general social network into sub-networks, and then you target the most important nodes of these sub-networks and so on until you run out of vaccines. The challenge will be to get good information about social networks, something not quite as easy as mapping computer networks, but there is progress on that front.

In one of the most dramatic illustrations of their technique, the researchers simulated the spread of a pandemic using data from a Swedish study of social connections, in which more than 310,000 people are represented and connected based on whether they live in the same household or they work in the same place. With the new method, the epidemic spread to about 4 percent of the population, compared to nearly 40 percent for more standard strategies, the team reports.

Source: ScienceNews. See also Lifeboat’s BioShield program.